What's new in enteric infectious diseases at home and abroad

Current Opinion in Infectious Diseases

Volumn 18, Issue 5, 2005, Pages 407-412

  DuPont, Herbert L ^a,b  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b ST LUKE S EPISCOPAL HOSPITAL   (United States)

Author keywords

Campylobacter; Clostridium difficile; Diarrhea; Diarrheagenic Escherichia coli; Travelers' diarrhea

Indexed keywords

ANTIINFECTIVE AGENT; AZITHROMYCIN; BACTERIAL VACCINE; BICOZAMYCIN; BISMUTH SALICYLATE; CIPROFLOXACIN; COTRIMOXAZOLE; LEVOFLOXACIN; METRONIDAZOLE; NITAZOXANIDE; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMYCIN; RIFAXIMIN; STREPTOMYCIN; SULFONAMIDE; TRIMETHOPRIM;

ANTIBIOTIC RESISTANCE; BACTEROIDES FRAGILIS; CAMPYLOBACTER; CLOSTRIDIUM DIFFICILE; DIARRHEA; DNA POLYMORPHISM; ESCHERICHIA COLI; FOOD INTAKE; GENETIC SUSCEPTIBILITY; HIGH RISK POPULATION; HUMAN; INFANTILE DIARRHEA; INTESTINE INFECTION; IRRITABLE COLON; MEDLINE; NONHUMAN; REVIEW; SALMONELLA; SHIGELLA; TRAVELLER DIARRHEA; TREATMENT FAILURE;

EID: 25144470074     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qco.0000182535.54081.68     Document Type: Review

References (70)

1. Cohen MB, Nataro JP, Bernstein DI, et al. Prevalence of diarrheagenic Escherichia coli in acute childhood enteritis: a prospective controlled study. J Pediatr 2005; 146:54-61. This study demonstrated that enteroaggregative E. coli was an underappreciated cause of pediatric diarrhea in one region of the USA.
2. Afset JE, Bevanger L, Romundstad P, Bergh K. Association of atypical enteropathogenic Escherichia coli (EPEC) with prolonged diarrhoea. J Med Microbiol 2004; 53 (Pt 11):1137-1144. A new pathogen known as atyptical enteropathogenic E. coli was identified in children under 5 years of age in Norway.
3. Pathela P, Hasan KZ, Roy E, et al. Enterotoxigenic Bacteroides fragilis-associated diarrhea in children 0-2 years of age in rural Bangladesh. J Infect Dis 2005; 191:1245-1252.
4. Obuch-Woszczatynski P, Wintermans RG, Van Belkum A, et al. Enterotoxigenic Bacteroides fragilis (ETBF) strains isolated in The Netherlands and Poland are genetically diverse. Pol J Microbiol 2004; 53:35-39.
5. Lynch M, Shieh WJ, Tatti K, et al. The pathology of rotavirus-associated deaths, using new molecular diagnostics. Clin Infect Dis 2003; 37:1327-1333.
6. Hoshino Y, Jones RW, Ross J, Kapikian AZ. Porcine rotavirus strain Gottfried-based human rotavirus candidate vaccines: construction and characterization. Vaccine 2005; 23:3791-3799.
7. Walker RI. Considerations for development of whole cell bacterial vaccines to prevent diarrheal diseases in children in developing countries. Vaccine 2005; 23:3369-3385.
8. Glass RI, Bresee JS, Parashar U, et al. Rotavirus vaccines: past, present, and future. Arch Pediatr 2005; 12:844-847. This review article focuses on the serious need for an effective rotavirus vaccine for the developing world where a half a million infants lose their life each year. The first licensed vaccine candidate had a short life span when a small number of immunized infants developed intussusception.
9. Widdowson MA, Bresee JS, Gentsch JR, Glass RI. Rotavirus disease and its prevention. Curr Opin Gastroenterol 2005; 21:26-31. The leading rotavirus vaccine candidates appear to be living attenuated rotavirus strains. They are appropriately being evaluated in developing regions where their need is the greatest.
10. Kassenborg HD, Smith KE, Vugia DJ, et al. Fluoroquinolone-resistant Campylobacter infections: eating poultry outside of the home and foreign travel are risk factors. Clin Infect Dis 2004; 38 (Suppl 3):S279-S284. Risk of acquisition of ciprofloxacin-resistant Campylobacter infection appears to be related to consumption of chicken outside the home and to international travel.
11. Nelson JM, Smith KE, Vugia DJ, et al. Prolonged diarrhea due to ciprofloxacin-resistant campylobacter infection. J Infect Dis 2004; 190:1150-1157. Ciprofloxacin-resistant Campylobacter produce more protracted diarrhea than Campylobacter diarrhea caused by susceptible strains. Use of antibiotics in animals may contribute to the emerging resistance.
12. Helms M, Simonsen J, Olsen KE, Molbak K. Adverse health events associated with antimicrobial drug resistance in Campylobacter species: a registry-based cohort study. J Infect Dis 2005; 191:1050-1055. Ciprofloxacin-resistance among Campylobacter isolates is becoming common worldwide. Resistant strains produce more severe disease with a 6-fold-increased risk of invasive illness, complicated course or death when compared with drug-susceptible strains.
13. Takahashi M, Koga M, Yokoyama K, Yuki N. Epidemiology of Campylobacter jejuni isolated from patients with Guillain-Barre and Fisher syndromes in Japan. J Clin Microbiol 2005; 43:335-339. Campylobacter is the most important definable cause of Guillain-Barré and Fisher syndromes. Some strains are more likely to produce the neurologic sequelae.
14. Mead PS, Slutsker L, Dietz V, et al. Food-related illness and death in the United States. Emerg Infect Dis 1999; 5:607-625.
15. Varma JK, Molbak K, Barrett TJ, et al. Antimicrobial-resistant nontyphoidal Salmonella is associated with excess bloodstream infections and hospitalizations. J Infect Dis 2005; 191:554-561. Antimicrobial-resistant strains of non-typhoid Salmonella more commonly lead to systemic infection bacteremic infection and need for hospitalization compared with susceptible strains. Animal use of antibacterial drugs may influence the resistance rate.
16. Helms M, Simonsen J, Molbak K. Quinolone resistance is associated with increased risk of invasive illness or death during infection with Salmonella serotype Typhimurium. J Infect Dis 2004; 190:1652-1654. Salmonella infection by fluoroquinolone-resistant strains are more likely to produce a severe outcome compared with infection by susceptible strains. Rates of Salmonella and Campylobacter resistance may relate to animal use of antibacterial drugs.
17. Beaugerie L, Flahault A, Barbut F, et al. Antibiotic-associated diarrhoea and Clostridium difficile in the community. Aliment Pharmacol Ther 2003; 17:905-912.
18. Arfons L, Ray AJ, Donskey CJ. Clostridium difficile infection among health care workers receiving antibiotic therapy. Clin Infect Dis 2005; 40:1384-1385. C. difficile is a potential danger to healthcare workers having contact with infected patients and taking antibacterial drugs.
19. Ray AJ, Donskey CJ. Clostridium difficile infection and concurrent vancomycin-resistant Enterococcus stool colonization in a health care worker: case report and review of the literature. Am J Infect Control 2003; 31:54-56.
20. Dallai RM, Harbrecht BG, Boujoukas AJ, et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 2002; 235:363-372.
21. Barbut F, Decre D, Lalande V, et al. Clinical features of Clostridium difficile-associated diarrhoea due to binary toxin (actin-specific ADP-ribosyltransferase)-producing strains. J Med Microbiol 2005; 54 (Pt 2):181-185. A new type of C. difficile toxin is emerging in many regions of the world. Detection of the strains requires special laboratory techniques.
22. McEllistrem MC, Carman RJ, Gerding DN, et al. A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes. Clin Infect Dis 2005; 40:265-272. Strains of C. difficile carrying a binary toxin may lead to severe disease and complicate diagnosis and therapy.
23. Al-Tureihi FI, Hassoun A, Wolf-Klein G, Isenberg H. Albumin, length of stay, and proton pump inhibitors: Key factors in Clostridium difficile-associated disease in nursing home patients. J Am Med Dir Assoc 2005; 6:105-108.
24. Cunningham R, Dale B, Undy B, Gaunt N. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect 2003; 54:243-245.
25. Dial S, Alrasadi K, Manoukian C, et al. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. Can Med Assoc J 2004; 171:33-38. This study shows that proton-pump inhibitors join traditional antibacterial drugs as predisposing factors for C. difficile diarrhea and colitis. C. difficile should be considered as a potential etiologic agent in patients who develop diarrhea while on a proton-pump inhibitor.
26. Musher DM, Aslam S, Logan N, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005; 40:1586-1590. This analysis provides evidence that metronidazole is not an effective form of therapy for C. difficile diarrhea and colitis and suggests new treatments are needed. Treatment failures and relapses show a very high rate with metronidazole.
27. Pepin J, Alary ME, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005; 40:1591-1597. Because of efficient absorption of the drug and the potential for spore formation of the pathogen, this treatment is associated with a high treatment failure rate. New treatments that do not increase the occurrence of vancomycin-resistant Enterococcus are needed.
28. McVay CS, Rolfe RD. In vitro and in vivo activities of nitazoxanide against Clostridium difficile. Antimicrob Agents Chemother 2000; 44:2254-2258.
29. Ripa S, Mignini F, Prenna M, Falcioni E. In vitro antibacterial activity of rifaximin against Clostridium difficile, Campylobacter jejunii and Yersinia spp. Drugs Exp Clin Res 1987; 13:483-488.
30. Bouckenooghe AR, Dupont HL, Jiang ZD, et al. Markers of enteric inflammation in enteroaggregative Escherichia coli diarrhea in travelers. Am J Trop Med Hyg 2000; 62:711-713.
31. Greenberg DE, Jiang ZD, Steffen R, et al. Markers of inflammation in bacterial diarrhea among travelers, with a focus on enteroaggregative Escherichia coli pathogenicity. J Infect Dis 2002; 185:944-949.
32. Jiang ZD, Okhuysen PC, Guo DC, et al. Genetic susceptibility to enteroaggregative Escherichia coli diarrhea: polymorphism in the interleukin-8 promotor region. J Infect Dis 2003; 188:506-511.
33. Al-Abri SS, Beeching NJ, Nye FJ. Traveller's diarrhoea. Lancet Infect Dis 2005; 5:349-360. This recent review focuses on new developments in travelers' diarrhea with a European perspective.
34. DuPont H. Travelers' diarrhea: antimicrobial therapy and chemoprevention. Nature Clin Pract Gastroenterol Hepatol 2005; 2:191-198. This review offers a perspective on the general problem of travelers' diarrhea and cites the important literature in the field. More than 50 million persons are put at risk each year, resulting in approximately 20 million cases of illness.
35. Kean BH. The diarrhea of travelers to Mexico. Summary of five-year study. Ann Intern Med 1963; 59:605-614.
36. Kean BH, Waters S. The diarrhea of travellers. I. Incidence in travelers returning to the United States from Mexico. AMA Arch Ind Health 1958; 18:148-150.
37. Kean BH, Schaffner W, Brennan RW. The diarrhea of travellers. V. Prophylaxis with phthalylsulfathiazole and neomycin sulphate. JAMA 1962; 180:367-371.
38. Kean BH, Waters SR. The diarrhea of travellers. III. Drug prophylaxis in Mexico. N Engl J Med 1959; 261:71-74.
39. Adachi JA, Jiang ZD, Mathewson JJ, et al. Enteroaggregative Escherichia coli as a major etiologic agent in traveler's diarrhea in 3 regions of the world. Clin Infect Dis 2001; 32:1706-1709.
40. Jiang ZD, Lowe B, Verenkar MP, et al. Prevalence of enteric pathogens among international travelers with diarrhea acquired in Kenya (Mombasa), India (Goa), or Jamaica (Montego Bay). J Infect Dis 2002; 185:497-502.
41. Jiang ZD, Mathewson JJ, Ericsson CD, et al. Characterization of enterotoxigenic Escherichia coli strains in patients with travelers' diarrhea acquired in Guadalajara, Mexico, 1992-1997. J Infect Dis 2000; 181:779-782.
42. Hoge CW, Gambel JM, Srijan A, et al. Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years. Clin Infect Dis 1998; 26:341-345.
43. von Sonnenburg F, Tornieporth N, Waiyaki P, et al. Risk and aetiology of diarrhoea at various tourist destinations. Lancet 2000; 356:133-134.
44. Ji S, Park H, Lee D, et al. Post-infectious irritable bowel syndrome in patients with Shigella infection. J Gastroenterol Hepatol 2005; 20:381-386. Bacterial pathogens are important causes of post-infectious IBS. This appears to be a chronic intestinal inflammatory complication of bacterial infection.
45. Spiller RC. Infection as a cause of irritable bowel syndrome. Hosp Med 2003; 64:270-274.
46. Spiller RC. Postinfectious irritable bowel syndrome. Gastroenterology 2003; 124:1662-1671.
47. Spiller RC, Jenkins D, Thornley JP, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000; 47:804-811.
48. Thornley JP, Jenkins D, Neal K, et al. Relationship of Campylobacter toxigenicity in vitro to the development of postinfectious irritable bowel syndrome. J Infect Dis 2001; 184:606-609.
49. Wang LH, Fang XC, Pan GZ. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut 2004; 53:1096-1101.
50. Okhuysen PC, Jiang ZD, Carlin L, et al. Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico. Am J Gastroenterol 2004; 99:1774-1778. This study demonstrated that 10% of young adults from the USA experiencing travelers' diarrhea developed new-onset IBS 6 months after leaving Mexico. The cohort not developing diarrhea in Mexico during the same time period did not experience this complication after leaving Mexico.
51. Owen JR. Diarrhoea at the Olympics. Br Med J 1968; 4:645.
52. DuPont HL, Ericsson CD, Johnson PC, et al. Prevention of travelers' diarrhea by the tablet formulation of bismuth subsalicylate. JAMA 1987; 257:1347-1350.
53. Steffen R, DuPont HL, Heusser R, et al. Prevention of traveler's diarrhea by the tablet form of bismuth subsalicylate. Antimicrob Agents Chemother 1986; 29:625-627.
54. DuPont HL, Galindo E, Evans DG, et al. Prevention of travelers' diarrhea with trimethoprim-sulfamethoxazole and trimethoprim alone. Gastroenterology 1983; 84:75-80.
55. Gomi H, Jiang ZD, Adachi JA, et al. In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing traveler's diarrhea in four geographic regions. Antimicrob Agents Chemother 2001; 45:212-216.
56. Rademaker CM, Hoepelman IM, Wolfhagen MJ, et al. Results of a double-blind placebo-controlled study using ciprofloxacin for prevention of travelers' diarrhea. Eur J Clin Microbiol Infect Dis 1989; 8:690-694.
57. Scott DA, Haberberger RL, Thornton SA, Hyams KC. Norfloxacin for the prophylaxis of travelers' diarrhea in U.S. military personnel. Am J Trop Med Hyg 1990; 42:160-164.
58. Wistrom J, Norrby SR, Burman LG, et al. Norfloxacin versus placebo for prophylaxis against travellers' diarrhoea. J Antimicrob Chemother 1987; 20:563-574.
59. Johnson PC, Ericsson CD, Morgan DR, et al. Lack of emergence of resistant fecal flora during successful prophylaxis of traveler's diarrhea with norfloxacin. Antimicrob Agents Chemother 1986; 30:671-674.
60. Gorbach S, Edelman R. Travelers' diarrhea: National Institutes of Health Consensus Development Conference. Rev Infect Dis 1986; 8 (Suppl 2): S109-S233.
61. DuPont HL, Ericsson CD. Prevention and treatment of traveler's diarrhea. N Engl J Med 1993; 328:1821-1827.
62. Farthing MJG, DuPont HL, Guandalini S, et al. Treatment and prevention of travellers' diarrhoea. Gastroenterol Int 1992; 5:162-175.
63. Ericsson CD, DuPont HL, Galindo E, et al. Efficacy of bicozamycin in preventing traveler's diarrhea. Gastroenterology 1985; 88:473-477.
64. Jiang ZD, DuPont HL. Rifaximin: in vitro and in vivo antibacterial activity - a review. Chemotherapy 2005; 51 (Suppl 1):67-72.
65. DuPont HL, Jiang ZD, Okhuysen PC, et al. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea. Ann Intern Med 2005; 142:805-812. This study demonstrated a 72-77% protection rate of rifaximin when used to prevent the occurrence of travelers' diarrhea among US students traveling to Mexico. The drug not only prevented acute diarrheal illness, but also milder forms of enteric illness, moderate and severe abdominal pain and cramps, and excess abdominal gas. The drug was not associated with side effects. This study should prompt more liberal use of chemoprophylaxis in travelers' diarrhea.
66. Taylor D, McKenzie R, Durbin A, et al. Double-blind, placebo-controlled trial to evaluate the use of rifaximin (200 mg TID) to prevent diarrhea in volunteers challenged with Shigella flexneri 2a (2457T). Am Soc Trop Med Hyg 2004; poster number 2079. Rifaximin prevented experimental infection against a virulent strain of Shigella, indicating value of the drug in prevention of invasive forms of infectious diarrhea.
67. DuPont HL, Reves RR, Galindo E, et al. Treatment of travelers' diarrhea with trimethoprim/sulfamethoxazole and with trimethoprim alone. N Engl J Med 1982; 307:841-844.
68. DuPont HL, Jiang ZD, Ericsson CD, et al. Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial. Clin Infect Dis 2001; 33:1807-1815.
69. Ashley DV, Walters C, Dockery-Brown C, et al. Interventions to prevent and control food-borne diseases associated with a reduction in traveler's diarrhea in tourists to Jamaica. J Travel Med 2004; 11:364-367.
70. Peltola H, Siitonen A, Kyronseppa H, et al. Prevention of travellers' diarrhoea by oral B-subunit/whole-cell cholera vaccine. Lancet 1991; 338:1285-1289.